TrialClinical rheumatology2026

Effect of ivarmacitinib on patient-reported outcomes in patients with moderate-to-severe active rheumatoid arthritis: a post-hoc analysis of a phase III trial.

Nannan Xia et al.PubMed ↗Publisher ↗

No numbers read from the abstract.